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Abstract
Background: Concerns that opioids may hasten death can be a cause of the physicians’ reluctance to prescribe
opioids, leading to inadequate symptom palliation. Our aim was to find if there was an association between
different opioid doses and the survival of the cancer patients that participated in our palliative care program.
Methods: A retrospective study was conducted at Ramathibodi Hospital, Bangkok between January 2013 and
December 2015. All of the cancer patients that were referred to palliative care teams by their primary physicians
were included in the study. The study data included the patients’ demographics, disease status, comorbidities,
functional status, type of services, cancer treatments, date of consultation, and the date of the patient’s death or
last follow-up. The information concerning opioid use was collected by reviewing the medical records and this
was converted to an oral morphine equivalent (OME), following a standard ratio. The time-varying covariate in the
Cox regression analysis was applied in order to determine the association between different doses of opioids and
patient survival.
Results: A total of 317 cancer patients were included in the study. The median (IQR) of the OME among our
patients was 6.43 mg/day (0.53, 27.36). The univariate Cox regression analysis did not show any association
between different opioid doses (OME ≤ 30 mg/day and > 30 mg/day) and the patients’ survival (p = 0.52).
The PPS levels (p < 0.01), palliative care clinic visits (HR 0.32, 95%CI 0.24–0.43), home visits (HR 0.75, 95%CI
0.57–0.99), chemotherapy (HR 0.32, 95%CI 0.22–0.46), and radiotherapy (HR 0.53, 95%CI 0.36–0.78) were
identified as factors that increased the probability of survival.
Conclusions: Our study has demonstrated that different opioid doses in advanced cancer patients are not
associated with shortened survival period.
Background
Opioids have been recommended by the WHO for
the first-line treatment of moderate to severe cancer
pain and the use of strong opioids for dyspnea man-
agement has been considered an efficacious and safe
treatment [1, 2]. Despite the availability of the drugs,
inadequate pain management has been found among
cancer patients [3, 4]. One of the most frequent
causes of undertreatment is misconceptions about
opioids [5–8].
There are still ongoing fears surrounding the use of
opioid analgesics among patients, families, and health
care professionals. A qualitative study revealed that
many patients and families believed that opioids should
be only used in terminal cases and at the end of life, and
that opioid use may be associated with premature death
[5]. Another study that attempted to identify the barriers
to cancer pain management in Taiwan demonstrated
that informed family caregivers of advanced cancer
patients had concerns about reporting pain and adminis-
tering opioids, particularly as they related to disease pro-
gression and possible side effects [7]. Additionally,
previous studies on the physician’s attitude toward pre-
scribing opioids for dyspnea showed that the most
frequently-reported barriers regarding the prescription
of opioids were the resistance of the patient, fear of
potential adverse effects, and fear of respiratory
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depression [6, 8]. A study in the Netherlands on the
perceptions of physicians concerning opioid use and
the survival of the patient showed that physicians
more often took hastening death into account when
they gave higher doses of opioids when the patient
experienced more severe symptoms and with female
patients [9].
With regard to the concerns of the potential
adverse events related to opioid use, the current evi-
dence regarding the effect of opioids on the patient’s
survival is still conflicting. Some studies have indi-
cated a potential association of increased survival with
higher doses of opioids or increases in opioid doses
in the last days of life [10–14]. Some studies on the
other hand did not show any significant survival dif-
ference between those that were taking opioids and
those that were not [15–17]. In other studies, higher
opioid doses or increasing doses of opioids were
reported to be associated with shorter survival, al-
though some of these did not examine the effect of
opioids on survival as a primary endpoint [18–20].
Several retrospective studies have suggested that opi-
oid use might promote tumor progression and as a
result negatively impact the survival of patients with
advanced cancer [21–23]. Additionally, opioid doses
have been seen to be correlated with low testosterone,
and hypogonadal males were seen to have a shorter
survival compared with those that were eugonadal
[24]. The analysis from a large chemotherapy RCT
showed that opioid use was independently associated
with shorter survival [25]. Regarding two recent sys-
tematic reviews on the association between systemic
opioid analgesia and survival among cancer patients
[26, 27], the results showed that there was no clear
association between opioid doses or increasing doses
of opioids and survival; other studies showed that
opioids might be associated with decreased survival,
while others suggested that opioids improved survival
or had no effect.
The Department of Family Medicine at Ramathibodi
Hospital, Mahidol University, had a project on the devel-
opment of palliative care for people in the Bangkok
metropolitan area beginning in 2010. The project is
aimed at the integration of palliative care services into
mainstream medicine in Thailand by providing a variety
of services, including inpatient consultation, a palliative
care clinic, telephone consultation, as well as providing
home-based palliative care. Around 700 patients and
their families participated in this project from January
2010 to December 2015. Among these patients, 90%
were diagnosed with cancer. The aim of this study was
to find if there was an association between different opi-
oid doses and the survival of the cancer patients that
participated in our palliative care program.
Methods
This retrospective cohort study was conducted in the
Department of Family Medicine at Ramathibodi
Hospital, Bangkok, Thailand, between January 2013
and December 2015. All of the patients with a cancer
diagnosis that were referred to palliative care teams
by their primary physicians, e.g., oncologists, surgeons
or internists (both inpatient and outpatient consult-
ation), were included into the study. The time from
the first palliative consultation to the study endpoints
was estimated for each subject. The endpoints of pa-
tient follow up were death, referral to other catch-
ment areas, or the end of the study period. The
study’s participants were censored, if they were re-
ferred to other catchment areas or were still alive at
the end of study period (December 31th, 2015). The
primary outcome was all-cause mortality.
Data collection
The study data were collected using a standardized
data record form. The data set was comprised of the
patient’s demographics (age, gender, marital status),
disease status (primary tumor sites, presence of
metastases), comorbidities assessed by using the
Charlson Comorbidity Index(CCI) [28], functional
status assessed using the Palliative Performance Scale
Adult Suandok, which was translated into Thai from
the Palliative Performance Scale (PPSv2) [29], types
of palliative care service, concurrent cancer treat-
ments, date of patient consultation with the palliative
care service, and the date of death or the patient’s
last follow-up.
Opioid dose
The information about opioid use for symptom palli-
ation (e.g., pain or dyspnea), both regular doses and
the number of breakthrough doses per day from the
initial consultation to the study endpoints, was col-
lected by reviewing the patient’s medical records. The
formulations and dosages of available opioids in
Thailand are summarized in Appendix. The use of
tramadol and methadone was excluded from the ana-
lysis due to their oral morphine equivalent not being
reliably established [30]. The daily opioid dose for
each type of opioid was then converted to an oral
morphine equivalent (OME), following a standard
ratio, as shown in Table 1 and 2.
The average daily opioid use of each patient during
those specific periods was calculated by using the
sum of the OME in that period divided by the num-
ber of days. For example, the average daily OME in
the first week = Sum of OME in the first weeks
divided by 7. Based on the previous data from our
palliative program, which showed that most patients
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survived 2–3 months after the palliative consultation,
we decided to calculate the average daily OME on a
weekly basis for the first three months and then on a
monthly basis until the study endpoints.
Statistical analysis
The opioid doses were categorized into 2 groups: 1) ≤
30 mg/day and 2) > 30 mg/day, based upon the
recommended total daily starting dose for opioids in
palliative care [31, 32]. The opioid dosages varied
according to time, depending on the symptom sever-
ity and clinical conditions of the patients. Therefore,
they were considered in the model as a time-
dependent variable. The survival probability among
the two categories of opioid doses was estimated
using Kaplan–Meier curves and they were compared
using the Log-rank test. The univariate Cox propor-
tional hazards regression model was applied to assess
the association between risk of death and different
opioid doses, as well as other possible prognostic
factors (i.e., age, sex, marital status, types of cancer,
services, and concurrent cancer treatments,
metastases, and baseline PPS and CCI). The multi-
variate Cox proportional hazards regression was
applied to determine the independent association be-
tween those variables and risk of death. Only the fac-
tors that had a P-value less than 0.15 from the
univariate model were considered in the multivariate
Cox proportional hazards model.
All of the analyses were performed using STATA ver-
sion 14. A P-value less than 0.05 was considered to be a
statistically-significant level.
Results
Four hundred and six patients received palliative care
from the Department of Family Medicine, Ramathi-
bodi Hospital, between January 2013 and December
2015. Eighty-nine patients that had non-cancer diag-
noses were excluded from the analysis. The age of the
study population ranged from 19 to 95 years, with a
median of 63 years. Forty-eight point nine percent
were female and only 11% had no evidence of metas-
tases at the time of the palliative consultation. The
major types of malignancies were gastrointestinal can-
cer (40.1%), primary lung cancer (18%), and head and
neck cancer (13.6%). The median PPS level was 40%
(ranging from 10% to 90%) and the median CCI score
was 3 (ranging from 0 to 39). The most prescribed
opioids in our study were morphine in different for-
mulations and fentanyl patch. The median (IQR) of
the OME among our patients was 6.43 mg/day (0.53,
27.36). Two of our patients did not receive any type
of opioid during the study period. Thirteen patients
(4.1%) received oral methadone during the study
period. Seventy-two patients (22.7%) received oral
tramadol and forty-nine patients (15.5%) received
intravenous tramadol. The median survival of the
patients was 33 days (ranging from 1 to 995 days).
The details of the characteristics of our study popula-
tion are depicted in Table 3.
The univariate Cox regression analysis revealed that
the patients with PPS levels of 40 to 60% and greater
than 70% had a higher chance of survival than pa-
tients with a PPS level of 30% and below 30%, with a
hazard ratio of 0.27 (95%CI 0.20–0.38) and 0.11
(95%CI 0.07–0.16) respectively. Moreover, a palliative
care clinic visit (HR 0.32, 95%CI 0.24–0.43), a home
visit (HR 0.75, 95%CI 0.57–0.99), chemotherapy (HR
0.32, 95%CI 0.22–0.46), and radiotherapy (HR 0.53,
95%CI 0.36–0.78) were identified as factors that in-
creased the probability of survival. On the other
hand, the patients that needed hospital admission
had a higher probability of dying (HR 2.03, 95%CI
1.54–2.67).
We did not find any difference in the survival
among the patients that received OME of ≤ 30 mg/
day and more than 30 mg/day (HR 1.14, 95%CI
0.77–1.69). The median survival time for OME ≤ 30
and > 30 was 47 days and 31 days. The medians
(IQR) of the OME in patients with OME ≤ 30 mg/day
and > 30 mg/day were 3.08 (0.22, 9.37) and 80 (42.98,
148.74) respectively. The results of our analysis are
shown in Table 4 and the survival curves of the two
groups of patients receiving different opioid doses
are shown in Fig. 1.
Previous preclinical studies have demonstrated that
morphine may lead to cancer progression via many
Table 1 Equianalgesic dose (mg) of different types of
opioids [47, 48]
Types of Opioids (Route) Oral Parenterala
Morphine sulfate 30 mg 10 mg (IV), 15 mg (SC)
Pethidine hydrochloride (IV) – 100 mg (IV)
Codeine phosphate tablet (Oral) 200 mg –
Fentanyl citrate (IV) – 0.1 mg
Methadone and Tramadol Morphine dose equivalence not
being reliably established
aIV intravenous route, SC subcutaneous route
Table 2 Equivalence between oral morphine and transdermal
fentanyl [48, 49]
Transdermal fentanyl Oral morphine
Fentanyl TTS 12 mcg/h 30 mg
Fentanyl TTS 25 mcg/h 60 mg
Fentanyl TTS 50 mcg/h 120 mg
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mechanisms in some specific types of cancer [21, 23].
Moreover, evidence from clinical practice has revealed
that individuals respond differently to opioids, and
that general differences between classes of opioids do
exist [33, 34]. Therefore, we decided to perform a
post hoc subgroup analysis of the association between
different morphine doses and the survival of palliative
care patients that had received only morphine. We
found that a higher dose of morphine (>30 mg/day)
was strongly associated with higher mortality (HR
4.09, 95%CI 1.89–8.78) with the median survival time
for OME ≤ 30 and > 30 at 47 days and 31 days re-
spectively. The multivariate Cox regression analysis,
adjusted by PPS, concurrent chemotherapy and radio-
therapy, palliative care clinic visit, hospital admission,
and home visit, also revealed the same result (HR
4.13, 95%CI 1.83–9.31), as shown in Table 5.
Discussion
Concerns that opioids may hasten death can be a
cause of physicians’ reluctance to prescribe or in-
crease the dosage of opioids in palliative care settings,
and could contribute to insufficient symptom palli-
ation in the latest stage of cancer. The present study
looked at the survival of cancer patients that received
palliative care in various settings, e.g., outpatient, in-
patient, and home care. We did not find any associ-
ation between different opioid doses and the survival
of the cancer patients in our palliative care program.
This finding agrees with clinical experience and the
findings of previous studies of palliative care popula-
tions [11–14, 16, 17, 35].
On the other hand, when we performed the post
hoc subgroup analysis to find out if there was any as-
sociation between different morphine doses and the
survival among patients that received morphine only,
we surprisingly found that a higher dose of morphine
was associated with shorter survival period. This find-
ing is consistent with the results from previous stud-
ies that showed the effects of morphine on cancer
progression/recurrence and survival with some spe-
cific types of cancers, although the effects of mor-
phine on these outcomes are still poorly understood
[21, 25, 36, 37]. It is also worth mentioning that these
effects have been explored in preclinical models using
morphine as the archetypical opioid [38]. Neverthe-
less, the number of patients with OME > 30 mg/day
in this subgroup analysis was very low and all died.
This could be one limitation of the analysis and we
believe that further, well-designed study is required to
clarify if there is an association between classes of
opioids and the survival of cancer patients. Moreover,
there may be other potential confounding factors,
such as the patients’ final symptom levels, that were
Table 3 Characteristics of the patients (N = 317)
Characteristics Number (%)




• Married 220 (69.4)
• Widowed 43 (13.6)
• Single 31 (9.8)
• Divorced 23 (7.3)
Types of malignancies
• Gastrointestinal cancer 127 (40.1)
• Primary lung cancer 57 (18)
• Head and neck cancer 43 (13.6)
• Genitourinary cancer 34 (10.7)
• Breast cancer 22 (6.9)
• Others 34 (10.7)
Metastases
No evidence of metastases at initial consultation 35 (11)
PPS level (%)a
• ≤ 30 130 (41)
• 40–60 102 (32.2)
• ≥ 70 65 (20.5)
Charlson comorbidity index
• ≤ 3 196 (61.8)
• > 3 121 (38.2)
Types of service
• Hospital admission 191 (60.3)
• Palliative care clinic visit 126 (39.7)
• Home visit 97 (30.6)
Concurrent cancer treatments
• Chemotherapy 62 (19.6)
• Radiotherapy 49 (15.5)
• Surgery 13 (4.1)
Types of opioidsb
• Morphine sulfate (Oral) 235 (74.1)
• Morphine sulfate (Intravenous) 155 (48.9)
• Morphine sulfate (Subcutaneous) 5 (1.6)
• Fentanyl TTS 12 mcg/h 70 (22.1)
• Fentanyl TTS 25 mcg/h 78 (24.6)
• Fentanyl TTS 50 mcg/h 56 (17.7)
• Fentanyl citrate (Intravenous) 22 (6.9)
• Pethidine hydrochloride (Intravenous) 16 (5)
• Codeine phosphate (Oral) 24 (7.6)
Patient status at the last follow-up
• Dead 228 (71.9)
• Alive 89 (28.1)
aN = 297, missing values in 20 patients (6.3%)
bN = 315, each patient could receive more than one type of opioid and two
patients did not receive any opioid
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not recorded in our study. Thus those patients need-
ing a higher dose of morphine might have worse
symptoms or at least need a higher dose to control
them. A more advanced disease might mean increased
levels of pain, necessitating higher doses of morphine.
Therefore, it is too early to come to a conclusion
concerning these effects of morphine in clinical
practice.
The patients participating in our study had a me-
dian survival of 33 days, ranging from 1 to 995 days.
This follow-up period was longer than that discussed
in previous literature, where the follow-ups were gen-
erally short, over days or only a short number of
weeks [39]. To the best of our knowledge, ours is
the first study to analyze opioid use from the time of
palliative consultation until the patient’s death by
using the time-dependent covariate analysis in the
Cox regression model, which represented the vari-
ation of actual opioid exposure better than measuring
only the increased dose or the opioid dose used dur-
ing the last days of life, as performed by other stud-
ies [14, 15, 18, 39, 40].
We also found that the higher Palliative Perform-
ance Scale, chemotherapy, and radiotherapy were
among the factors strongly correlated with longer
survival of the patients, which was consistent with
previous reports [41–44]. Moreover, the patients that
visited the palliative care clinic or had a home visit








• Female 113 (72.9) 1.0 – 0.36
• Male 115 (71) 0.89 0.68,1.15
Age
• Age < 60 86 (68.3) 1.0 – 0.96
• Age ≥ 60 142 (74.4) 1.01 0.77,1.32
Marital status
• Married 153 (69.6) 1.0 – 0.62
• Divorced 19 (82.6) 1.30 0.81,2.10
• Widowed 33 (76.7) 1.03 0.71,1.51
• Single 23 (74.2) 1.23 0.80,1.91
Type of malignancy
• Head and neck cancer 26 (60.5) 1.0 – 0.26
• Breast cancer 16 (72.7) 1.40 0.75,2.62
• Primary lung cancer 41 (71.9) 1.09 0.66,1.78
• Gastrointestinal cancer 99 (78) 1.51 0.98,2.34
• Genitourinary cancer 24 (70.6) 1.07 0.62,1.87
• Others 22 (67.7) 1.15 0.65,2.03
Metastases
Evidence of metastases at
consultation
204 (72.3) 1.0 – 0.33
No metastases 24 (68.5) 0.81 0.53,1.24
PPS (%)
• ≤ 30 113 (86.9) 1.0 – <0.01
• 40–60 73 (71.6) 0.27 0.20,0.38
• ≥ 70 30 (46.2) 0.11 0.07,0.16
Type of service
• No home visit 151 (68.6) 1.0 – 0.04
• Home visit 77 (79.4) 0.75 0.57,0.99
• No palliative care clinic visit 154 (80.6) 1.0 – <0.01
• Palliative care clinic visit 74 (58.7) 0.32 0.24,0.43
• No hospital admission 81 (64.3) 1.0 – <0.01
• Having hospital admission 147 (77) 2.03 1.54,2.67
Concurrent treatment
• No chemotherapy 195 (76.5) 1.0 – <0.01
• Receiving chemotherapy 33 (53.2) 0.32 0.22,0.46
• No radiotherapy 198 (73.9) 1.0 – <0.01
• Receiving radiotherapy 30 (61.2) 0.53 0.36,0.78
• No surgery 220 (72.4) 1.0 – 0.12
• Receiving surgery 8 (61.5) 0.60 0.29,1.20
Charlson comorbidity index (CCI)
• ≤ 3 132 (67.7) 1.0 – 0.26
• > 3 95 (78.5) 1.16 0.89,1.52
Table 4 Univariate Cox regression analysis of factors associated
with survival (Continued)
Oral morphine equivalent (mg/day)
• ≤ 30 mg/day 170 (69.7) – – 0.52
• > 30 mg/day 58 (79.5) 1.14 0.77,1.69
Fig. 1 Survival curves of the study population categorized by oral
morphine equivalent
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tended to survive longer, and the patients that
needed hospital admission lived a shorter length of
time in our study. This could be explained by the
fact that only patients with good clinical or func-
tional status survived long enough to receive those
interventions, and those with complex conditions
that needed hospital admission had a greater chance
of dying earlier.
Limitations
There are some limitations of our study worth men-
tioning. Since our study was a retrospective cohort
study, the sample was not randomly determined.
Other variables or residual confounders could have
affected the differences between groups. It is worth
mentioning that the doses of methadone and trama-
dol were not included in the analysis. Although, few
patients received those opioids, this might have
affected the results of the study to some extent. Most
of the patients in our study were exposed to rela-
tively low doses of opioids and this may have led to
a “floor effect” where we may not have seen the sig-
nificant difference in the survival among patients
with different opioid doses in our study. Additionally,
a patient’s survival is influenced by many complex
factors that may not be measurable. For example,
depression was identified as a factor associated with
mortality among advanced cancer patients in a longi-
tudinal study [45]. The effect of opioids on survival
may be from better pain relief, which may interact
with the patient’s psychological distress or depres-
sion. Moreover, most of our cancer patients survived
for a few months after the palliative consultation.
Therefore, the chronic effect (months to years) of
opioids on survival was not adequately illustrated in
this study. Further, there are wide differences in pub-
lished opioid equianalgesic ratios and critical individ-
ual factors, such as gender differences, organ
dysfunction, bidirectional differences of equivalence
with certain opioids, drug interactions, and interindi-
vidual differences in pharmacokinetics and pharmaco-
dynamics, which may impact equianalgesic doses
[46]. Therefore, the calculated equianalgesic dose to
oral morphine in this study may represent only the
estimated opioid exposure and not the real-life
exposure for each individual patient.
Conclusion
Our study has demonstrated that the use of opioids
of different doses in the palliative care population is
not associated with shortened survival time. Based on
our available data, we recommend that opioids be
continued for pain control in patients with advanced
cancer, as the ultimate goal of palliative care is to
provide patients with the best quality of life during
the trajectory of the illness. Nevertheless, future clin-
ical research is required to clarify if there are any as-
sociations between different classes of opioids and the
survival of cancer patients.
Appendix
Table 5 Cox regression analysis of the association between different morphine doses and the survival among palliative care patients
that received morphine only (N = 118)
Morphine doses Number of deathsa (%) Hazard ratio (95%CI) P-value Adjusted Hazard
ratiob (95%CI)
P-value
• ≤ 30 mg/day 82 (72.57) – –
• > 30 mg/day 5 (100) 4.08 (1.89,8.78) <0.01 4.13 (1.83, 9.31) <0.01
aN = 118
bAdjusted by PPS, chemotherapy, radiotherapy, palliative care clinic visit, hospital admission, and home visit
Table 6 Formulations and dosages of available opioids in
Thailand [50]
Formulations Available dosages
Tramadol hydrochloride (injectable form) 50 mg/ml




Morphine sulfate (injectable form) 10 mg/ml
Morphine sulfate (immediate release
oral solution)
2 mg/ml
Morphine sulfate (immediate release
tablet)
10 mg
MST Continus (sustained release morphine
tablet)
10 mg, 30 mg, 60 mg
Kapanol (sustained release morphine
capsule)
20 mg, 50 mg, 100 mg
Pethidine hydrochloride (injectable form) 50 mg/ml
Fentanyl GPO TTSa 12 mcg/h, 25 mcg/h,
50 mcg/h
Fentanyl citrate (injectable form) 0.1 mg/ml
Codeine phosphate (tablet) 15 mg, 30 mg
Methadone hydrochloride (tablet) 10 mg
aManufactured by Hexal AG, Germany
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